Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck does not yet know why DSMB decided no longer to study vorapaxar in stroke and ACS patients, but market analysts suspect a finding of excess bleeding.

You may also be interested in...



Merck’s CV Pipeline: A Shrinking But Strident Commitment

Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.

Related Content

Topics

UsernamePublicRestriction

Register

PS071692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel